Use of pneumatic nebulization and laser ablation-inductively coupled plasma-mass spectrometry to study the distribution and bioavailability of an intraperitoneally administered Pt-containing chemotherapeutic drug.
about
Mass spectrometry imaging of therapeutics from animal models to three-dimensional cell culturesQuantitative bioimaging of trace elements in the human lens by LA-ICP-MS.Quantitative bioimaging by LA-ICP-MS: a methodological study on the distribution of Pt and Ru in viscera originating from cisplatin- and KP1339-treated mice.Extravasation of Pt-based chemotherapeutics - bioimaging of their distribution in resectates using laser ablation-inductively coupled plasma-mass spectrometry (LA-ICP-MS).Tumor microenvironment in focus: LA-ICP-MS bioimaging of a preclinical tumor model upon treatment with platinum(IV)-based anticancer agents.Recent advances in quantitative LA-ICP-MS analysis: challenges and solutions in the life sciences and environmental chemistry.Quantitative imaging of platinum based on laser ablation-inductively coupled plasma-mass spectrometry to investigate toxic side effects of cisplatin.LA-ICP-MS imaging in multicellular tumor spheroids - a novel tool in the preclinical development of metal-based anticancer drugs.Printing metal-spiked inks for LA-ICP-MS bioimaging internal standardization: comparison of the different nephrotoxic behavior of cisplatin, carboplatin, and oxaliplatin.A comparison of sample preparation strategies for biological tissues and subsequent trace element analysis using LA-ICP-MS.Application of imaging mass spectrometry approaches to facilitate metal-based anticancer drug research.Pharmacokinetics and tissue distribution of novel platinum containing anticancer agent BP-C1 studied in rabbits using sector field inductively coupled plasma mass spectrometry.Review of the applications of laser ablation inductively coupled plasma mass spectrometry (LA-ICP-MS) to the analysis of biological samples
P2860
Q26820859-26BA86F4-D7CE-4FE6-9E9C-34A6AA8F2019Q35087110-1798B867-19DB-4674-90D6-4DD2D3872E5EQ35167846-213C7D39-7EAC-424C-8BE8-3142BB25546AQ35557391-79AD958B-1680-4CA6-AC2D-9E272C282D85Q35598162-196187CB-5E2F-4457-91AC-E5F8FA913431Q35689805-170DFC2A-CCB6-4642-8973-065C7C680AFFQ35811787-097DFE8A-1AD3-45EC-80B0-A2A12601AAC7Q35902867-8CEAD130-C6DD-4BF8-B0B4-1510BE31D967Q35908682-0D1BDD2B-0679-497C-A9C0-28430BF16A03Q36223024-B27BF45A-1EFF-4BE6-BE85-4ED10F246D62Q36268494-1F114CF3-E09E-4992-A516-28CE6F45BCB8Q38275908-10EEB0F9-BA00-4B6E-AE38-87C40ABD8826Q56700302-2F2B4674-37C8-402C-AC80-C67CAEE4DC6D
P2860
Use of pneumatic nebulization and laser ablation-inductively coupled plasma-mass spectrometry to study the distribution and bioavailability of an intraperitoneally administered Pt-containing chemotherapeutic drug.
description
2012 nî lūn-bûn
@nan
2012 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Use of pneumatic nebulization ...... taining chemotherapeutic drug.
@ast
Use of pneumatic nebulization ...... taining chemotherapeutic drug.
@en
Use of pneumatic nebulization ...... taining chemotherapeutic drug.
@nl
type
label
Use of pneumatic nebulization ...... taining chemotherapeutic drug.
@ast
Use of pneumatic nebulization ...... taining chemotherapeutic drug.
@en
Use of pneumatic nebulization ...... taining chemotherapeutic drug.
@nl
prefLabel
Use of pneumatic nebulization ...... taining chemotherapeutic drug.
@ast
Use of pneumatic nebulization ...... taining chemotherapeutic drug.
@en
Use of pneumatic nebulization ...... taining chemotherapeutic drug.
@nl
P2860
P1476
Use of pneumatic nebulization ...... taining chemotherapeutic drug.
@en
P2093
Deepti Gholap
Johanna Verhulst
P2860
P2888
P304
P356
10.1007/S00216-011-5654-3
P407
P577
2012-01-15T00:00:00Z